NanoViricides (NNVC) Competitors $1.53 -0.01 (-0.39%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NNVC vs. COYA, CHRS, MGNX, CLYM, PLRX, ANIX, ONCY, ZNTL, SRZN, and VIRIShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Oncolytics Biotech (ONCY), Zentalis Pharmaceuticals (ZNTL), Surrozen (SRZN), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. Its Competitors Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences Oncolytics Biotech Zentalis Pharmaceuticals Surrozen Virios Therapeutics Coya Therapeutics (NASDAQ:COYA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations. Does the media favor COYA or NNVC? In the previous week, Coya Therapeutics had 6 more articles in the media than NanoViricides. MarketBeat recorded 6 mentions for Coya Therapeutics and 0 mentions for NanoViricides. Coya Therapeutics' average media sentiment score of 0.59 beat NanoViricides' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Positive NanoViricides Neutral Do insiders & institutionals have more ownership in COYA or NNVC? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher earnings and valuation, COYA or NNVC? NanoViricides has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M29.17-$14.88M-$1.07-5.79NanoViricidesN/AN/A-$8.29M-$0.70-2.19 Is COYA or NNVC more profitable? Coya Therapeutics' return on equity of -48.88% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -48.88% -43.32% NanoViricides N/A -87.90%-78.69% Which has more volatility & risk, COYA or NNVC? Coya Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Do analysts rate COYA or NNVC? Coya Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 166.56%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCoya Therapeutics beats NanoViricides on 10 of the 14 factors compared between the two stocks. Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$24.54M$789.33M$5.50B$20.82BDividend YieldN/A4.84%4.59%3.65%P/E Ratio-2.121.1629.9728.42Price / SalesN/A25.58445.5259.91Price / CashN/A19.5624.8117.60Price / Book2.326.548.704.66Net Income-$8.29M-$4.39M$3.26B$994.60M7 Day Performance-2.91%1.29%0.53%1.23%1 Month Performance9.96%-0.20%3.29%0.22%1 Year Performance-13.33%23.02%45.87%17.65% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricides0.3311 of 5 stars$1.53-0.4%N/A-18.5%$24.54MN/A-2.1220COYACoya Therapeutics2.1362 of 5 stars$6.34+4.1%$16.50+160.3%+1.5%$101.86M$3.55M-5.936News CoverageEarnings ReportCHRSCoherus Oncology4.2358 of 5 stars$0.87-1.1%$4.68+439.6%-38.4%$101.77M$266.96M-0.77330MGNXMacroGenics4.4008 of 5 stars$1.64+3.8%$5.33+225.2%-58.2%$99.68M$149.96M-1.84430CLYMClimb Bio2.7438 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoverageEarnings ReportUpcoming EarningsGap UpHigh Trading VolumePLRXPliant Therapeutics3.8678 of 5 stars$1.70+7.6%$13.31+683.1%-86.2%$96.99M$1.58M-0.4790Earnings ReportAnalyst ForecastANIXAnixa Biosciences3.6068 of 5 stars$3.26+8.3%$9.00+176.1%-6.4%$96.96M$210K-8.585ONCYOncolytics Biotech2.3495 of 5 stars$0.88-10.8%$4.33+390.7%-10.6%$96.43MN/A-3.0530Earnings ReportGap DownZNTLZentalis Pharmaceuticals2.4974 of 5 stars$1.39+3.7%$8.37+501.9%-53.3%$96.42M$67.43M-0.44160News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionSRZNSurrozen2.8068 of 5 stars$10.71-2.7%$38.50+259.6%+39.6%$94.19M$10.65M-0.4380Earnings ReportGap UpVIRIVirios Therapeutics0.112 of 5 stars$4.85+0.3%$5.00+3.1%+2,702.3%$93.40MN/A-17.965 Related Companies and Tools Related Companies Coya Therapeutics Alternatives Coherus Oncology Alternatives MacroGenics Alternatives Climb Bio Alternatives Pliant Therapeutics Alternatives Anixa Biosciences Alternatives Oncolytics Biotech Alternatives Zentalis Pharmaceuticals Alternatives Surrozen Alternatives Virios Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NNVC) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access